Lant Medical raises £500k from Innovate UK and angel investors to design clinical trials.
The funding will support the design, manufacturing, and field trials of a non-antibiotic treatment for Helicobacter pylori.
Share allotment filed at Companies House
Lant Medical is a health tech company based in the North East that develops non-antibiotic treatments for Helicobacter pylori infections.
Lant Medical has secured £500k in funding to design a clinical trial for its non-antibiotic treatment targeting Helicobacter pylori bacteria. The capital is split between Innovate UK and two angel investors from the Northern Investor Hub.
The investment will support clinical trial design, manufacturing, and field trials in India to validate the treatment efficacy. The formulation aims to offer an alternative to standard antibiotics for resistant infections, potentially reducing pressure on the NHS and avoiding adverse side effects for patients.
From the founder
"I’m excited by the possibility for this treatment to help a lot of people, benefiting their overall health and avoiding the misery of side effects from antibiotics."
Joanne Lant
Founder at Lant Medical
Investor perspective
"Supporting Lant Medical has been incredibly rewarding."
Charlotte Scott
Senior Investor Relations Manager, UMi
Use of funds
- 01Fund research and development
Investors
Categories
About the company
Lant Medical
Developing targeted non-antibiotic treatments for bacterial infections.